Skip to content
Home/Companies/Biotech/Soleno Therapeutics
Soleno Therapeutics

Soleno Therapeutics

Biotech·US·Exited 2026·Held 8yr
Entry
2018
Hold
8yr
Exit
2026

Who owns Soleno Therapeutics?

Soleno Therapeutics is an American Biotech company, now owned by Neurocrine Biosciences, which acquired it in 2026 from Abingworth.

Hand-verified · updated 2026-07-08

Open JSON · CC-BY
Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Websitesoleno.life
Exit Type
Trade Sale
Buyer
Neurocrine Biosciences
Exit Year
2026

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to Merck & Co.
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Tizona Therapeutics
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
MedTechFrance· 2015
Avedro
Exited 2019
MedTechUS· 2014
to Glaukos

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Soleno Therapeutics?

Soleno Therapeutics is now owned by Neurocrine Biosciences, which acquired it in 2026 from Abingworth.

When did Neurocrine Biosciences acquire Soleno Therapeutics?

Neurocrine Biosciences acquired Soleno Therapeutics in 2026, buying from Abingworth.

Who did Soleno Therapeutics sell to?

Abingworth sold Soleno Therapeutics to Neurocrine Biosciences in 2026 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue